Alvotech (ALVO) Cash from Financing Activities (2023 - 2026)
Alvotech's (ALVO) quarterly Cash from Financing Activities came in at -$967000.0 in Q1 2026, up 83.44% YoY from -$527150.9 in Q1 2025, and down 100.36% on a QoQ basis from $270.8 million in Q4 2025.
Alvotech (ALVO) Cash from Financing Activities (2023 - 2026) Analysis & Trends
Alvotech (ALVO) has 4 years of Cash from Financing Activities data on file, last reported at -$967000.0 in Q1 2026.
- Quarterly Cash from Financing Activities rose 83.44% year-over-year to -$967000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $275.7 million (up 74.18% YoY) and the FY2025 annual result came in at $270.8 million, down 8.9% from the prior year.
- Cash from Financing Activities fell to -$967000.0 in Q1 2026, from $270.8 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $297.0 million in Q4 2024 to a low of -$136.9 million in Q3 2024.
- A 4-year average of $61.0 million and a median of $12.3 million in 2023 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 1977.64% in 2025, down 104.38% in 2025.
- Tracing ALVO's Cash from Financing Activities over 4 years: stood at $20.7 million in 2023, then soared by 1337.55% to $297.0 million in 2024, then decreased by 8.84% to $270.8 million in 2025, then tumbled by 100.36% to -$967000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$967000.0 (Q1 2026), $270.8 million (Q4 2025), and -$77.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Alvotech | 1.23 Bn | 1.23 Bn | 5.09 Mn | -967,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -967,000.00 |
| Mar 31, 2026 | -967,000.00 |
| Dec 31, 2025 | 270.77 Mn |
| Dec 31, 2025 | 270.77 Mn |
| Sep 30, 2025 | -77.24 Mn |
| Sep 30, 2025 | -77.24 Mn |
| Jun 30, 2025 | 83.15 Mn |
| Jun 30, 2025 | 83.15 Mn |
| Mar 31, 2025 | -5.84 Mn |
| Mar 31, 2025 | -5.84 Mn |
| Dec 31, 2024 | 297.01 Mn |
| Dec 31, 2024 | 297.01 Mn |
| Sep 30, 2024 | -136.89 Mn |
| Sep 30, 2024 | -136.89 Mn |
| Jun 30, 2024 | 4.00 Mn |
| Jun 30, 2024 | 4.00 Mn |
| Mar 31, 2024 | 133.18 Mn |
| Mar 31, 2024 | 133.18 Mn |
| Dec 31, 2023 | 20.66 Mn |
| Dec 31, 2023 | 20.66 Mn |